The Lynx Group

Web Exclusives

Web Exclusives — September 11, 2020
The small-molecule inhibitor of tyrosine kinase WEE1 adavosertib demonstrated promising clinical activity in a single-arm, phase 2 study of patients with unselected uterine serous cancer (USC), with an objective response rate of 29.4%, said Joyce F. Liu, MD, MPH, Director of Clinical Research, Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, MA, at the ASCO 2020 virtual annual meeting.
Read Article

Web Exclusives — September 10, 2020
Cranbury, NJ – Starting October 13, the Association for Value-Based Cancer Care (AVBCC) will present its 10th Annual Summit as a 10-week series with approximately 30 WEBside chats. The 10th Association for Value-Based Cancer Care Summit & Education WEBside chats will feature top influencers; future trends; balanced opinions; real-time, real-world information; and unfiltered discussions. Each chat will run for approximately 90 minutes on alternating Tuesday, Wednesday, Thursday and/or Friday sessions delivered at 8:00 am ET and rebroadcast at 4:30 pm PT.
Read Article

Web Exclusives — August 11, 2020
David DeRemer, PharmD, BCOP, FCCP, FHOPA, Clinical Associate Professor, University of Florida College of Pharmacy, shares insights about cancer drugs and COVID-19 in this interview that followed a segment of the Association for Value-Based Cancer Care (AVBCC) webinar series COVID-19 Recovery, the Road Ahead, in which he recently took part.
Read Article

Web Exclusives — June 22, 2020
On June 15, 2020, the FDA accelerated the approval of lurbinectedin (Zepzelca; Jazz Pharma/Pharma Mar), an intravenous alkylating drug, for the treatment of adults with metastatic small-cell lung cancer that has progressed during or after platinum-based chemotherapy. The FDA granted lurbinectedin an orphan drug designation for this indication.
Read Article

Web Exclusives — June 22, 2020
On June 10, 2020, the FDA accelerated the approval of a new indication for nivolumab (Opdivo; Bristol Myers Squibb), a PD-1 inhibitor, for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous-cell carcinoma after fluoropyrimidine-based and platinum-based chemotherapy. Nivolumab has been previously approved for many indications, but this is its first indication for esophageal cancer.
Read Article

Web Exclusives — June 16, 2020
San Francisco, CA—If you know someone who has cancer, reaching out could be the medicine he or she needs. According to data presented at the 2019 ASCO Supportive Care in Oncology Symposium, increased social support may function as an analgesic that helps to mitigate one of the most common symptoms experienced by patients with cancer—pain.
Read Article

Web Exclusives — June 16, 2020
San Francisco, CA—Reducing pain without increasing the use of opioids is feasible in patients with advanced cancer, according to the results of a retrospective analysis presented at the 2019 ASCO Supportive Care in Oncology Symposium. Among the 300 patients seen by an inpatient palliative care team, 50% of patients achieved clinically improved pain control without an increase in oral morphine-equivalent daily dose.
Read Article

Web Exclusives — June 16, 2020
San Francisco, CA—Although there is a biological rationale that supports the “abscopal” effects of radiation therapy plus checkpoint immunotherapy in fighting cancer, this combination showed mixed results and no robust effects in patients with metastatic renal-cell carcinoma (RCC), according to results of 2 preliminary studies presented at the 2020 Genitourinary Cancers Symposium.
Read Article

Web Exclusives — June 8, 2020
On May 29, 2020, the FDA approved ramucirumab (Cyramza; Eli Lilly) in combination with erlotinib (Tarceva) for first-line treatment of patients with metastatic non–small-cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations. Ramucirumab was previously approved for several types of cancer, including, in combination with docetaxel, for metastatic NSCLC, after platinum-based chemotherapy.
Read Article

Web Exclusives — June 2, 2020
On May 26, 2020, the FDA approved nivolumab (Opdivo; BMS) and ipilimumab (Yervoy; BMS) plus chemotherapy as first-line treatment of recurrent or metastatic squamous or nonsquamous non–small-cell lung cancer (NSCLC), regardless of PD-L1 expression, and with no EGFR or ALK aberrations. On May 15, the FDA approved nivolumab plus ipilimumab as first-line treatment of metastatic NSCLC with PD-L1 ≥1% expression.
Read Article

Page 1 of 9

Subscribe to
Value-Based Cancer Care

Stay up to date with personalized medicine by subscribing to recieve the free VBCC print publication or weekly e‑Newsletter.

I'd like to recieve: